

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS EXPRESS			February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:36:12 ON 02 OCT 2002

=>

=> file medline embase biosis scisearch caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 15:36:30 ON 02 OCT 2002

FILE 'EMBASE' ENTERED AT 15:36:30 ON 02 OCT 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:36:30 ON 02 OCT 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'SCISEARCH' ENTERED AT 15:36:30 ON 02 OCT 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 15:36:30 ON 02 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s antibod?

L1 2351052 ANTIBOD?

=> s l1 and CD23

L2 3213 L1 AND CD23

=> s l2 and chimeric

L3 84 L2 AND CHIMERIC

=> s l3 and IgG1

L4 7 L3 AND IGG1

=> dup remove l4

PROCESSING COMPLETED FOR L4

L5 3 DUP REMOVE L4 (4 DUPLICATES REMOVED)

=> d l5 1-3 cbib abs

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS

1999:736930 Document No. 131:350265 **Antibodies to CD23.**

Bonnefoy, Jean-Yves Marcel Paul; Crowe, Scott James; Ellis, Jonathan Henry; Rapson, Nicholas Timothy; Shearin, Jean (Glaxo Group Limited, UK). PCT Int. Appl. WO 9958679 A1 19991118, 81 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-GB1434 19990507. PRIORITY: GB 1998-9839 19980509.

AB The authors disclose the prepn. and characterization of murine monoclonal and humanized **antibodies** which bind to the **CD23** (Fc.epsilon.RII receptor) antigen. In one example, humanized **IgG1**

, with mutations to eliminate Clq and Fc binding, was shown to bind to **CD23** with assocn. rates of the order of  $1.5-1.85 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$  and to not exhibit complement activation or ADCC. The authors suggest these **antibodies** may find use in the treatment of autoimmune and inflammatory disorders.

- L5 ANSWER 2 OF 3 MEDLINE DUPLICATE 1  
96148598 Document Number: 96148598. PubMed ID: 8550069. Regulation and targeting of T-cell immune responses by IgE and IgG **antibodies**. Bheekha Escura R; Wasserbauer E; Hammerschmid F; Pearce A; Kidd P; Mudde G C. (Department of Immuno-Dermatology, SANDOZ Research Institute, Vienna, Austria. ) IMMUNOLOGY, (1995 Nov) 86 (3) 343-50. Journal code: 0374672. ISSN: 0019-2805. Pub. country: ENGLAND: United Kingdom. Language: English.
- AB A set of **chimeric antibodies** with identical F(ab')<sub>2</sub> fragments specific for the hapten 5-iodo-4-hydroxyl-3-nitrophenacetyl (NIP), but with different human Fc parts (gamma 1, gamma 2, gamma 3, gamma 4, epsilon), was used to compare the role of IgG and IgE **antibodies** in antigen presentation by human Epstein-Barr virus (EBV) B cells. Two or three molecules of NIP were coupled to one molecule of Der pI (Der pI-(3)NIP), a major allergen of Dermatophagoides pteronyssinus. Both monomeric IgG and performed complexes of various Der pI/IgG ratios failed to bind significantly to the Fc receptor for IgG on B cells (Fc gamma RII; CD32). Binding of IgG3 (> **IgG1**)-containing complexes (optimal ratio of antigen to **antibody** = 1:1) could be enhanced by increasing the number of haptens per Der pI molecule to nine or more. However, antigen presentation mediated by IgG and CD32 was not seen with either pulsed B cells or B cells that were allowed to capture the IgG complexes during the whole stimulation period. IgE binding to **CD23** and subsequent IgE-mediated antigen presentation was seen under all conditions tested. Even monomeric immune complexes (IC) (Der pI-(3)NIP/IgE), in the absence of **CD23** cross-linking, induced an immune response. As the number of natural epitopes for human **antibodies** on Der pI was less than five, we conclude that, in vivo, complexes consisting of Der pI/IgG will be directed to antigen-presenting cells expressing the high-affinity receptor for IgG (CD64), whereas IgE will allow antigen presentation by **CD23**-expressing cells, including B cells.

- L5 ANSWER 3 OF 3 SCISEARCH COPYRIGHT 2002 ISI (R) DUPLICATE 2  
91:565320 The Genuine Article (R) Number: GJ565. CHARACTERIZATION OF NEW RAT ANTI-MOUSE IGE MONOCLONALS AND THEIR USE ALONG WITH **CHIMERIC** IGE TO FURTHER DEFINE THE SITE THAT INTERACTS WITH FC-EPSILON-RII AND FC-EPSILON-RI. KEEGAN A D; FRATAZZI C; SHOPE B; BAIRD B; CONRAD D H (Reprint). DEPT MICROBIOL & IMMUNOL, BOX 678, MCV STN, RICHMOND, VA, 23298; STANFORD UNIV, DEPT CELL BIOL, STANFORD, CA, 94305; JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP, DEPT MED, DIV MOLEC RHEUMATOL, BALTIMORE, MD, 21239; BECTON DICKERSON RES CTR, MT VIEW, CA, 94039; CORNELL UNIV, DEPT CHEM, ITHACA, NY, 14853. MOLECULAR IMMUNOLOGY (1991) Vol. 28, No. 10, pp. 1149-1154. Pub. country: USA. Language: ENGLISH.  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*
- AB Three rat monoclonal **antibodies** specific for mouse IgE (C12B9, 23G3, and B1E3) were established by using monoclonal anti-DNP mouse IgE (mIgE) as immunogen. These **antibodies**, as well as a fourth, (R1E4) were characterized. It was found that one **antibody** (C12B9) recognizes an allotypic determinant (Igh-7a) found on the C-epsilon chain of mIgE. **Antibody** cross-blocking studies and epitope mapping studies using recombinant mIgE indicated that 3 **antibodies** (C12B9, R1E4 and 23G3) were directed against the C-epsilon-3 domain while one (B1E3) was directed against the C-epsilon-4 domain. A highly specific sandwich RIA for mIgE was developed using these **antibodies**. Use of these monoclonal anti-mIgE **antibodies** in conjunction with recombinant **chimeric** mIgE-human **IgG1** molecules, demonstrated that the C-epsilon-3 domain is important in the

binding of mIgE to the murine B cell Fc-epsilon-RII as well as to the murine mast cell Fc-epsilon-RI. The presence of the C-epsilon-4 domain influenced the binding of the recombinant IgE to the Fc-epsilon-RII; in contrast to the C-epsilon-4 domain had no effect on binding to the Fc-epsilon-RI.

=> d his

(FILE 'HOME' ENTERED AT 15:36:12 ON 02 OCT 2002)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 15:36:30 ON 02 OCT 2002

L1 2351052 S ANTIBOD?  
L2 3213 S L1 AND CD23  
L3 84 S L2 AND CHIMERIC  
L4 7 S L3 AND IGG1  
L5 3 DUP REMOVE L4 (4 DUPLICATES REMOVED)

=> s l3 and IgG3

L6 5 L3 AND IGG3

=> dup remove l6

PROCESSING COMPLETED FOR L6

L7 1 DUP REMOVE L6 (4 DUPLICATES REMOVED)

=> d l7 cbib abs

L7 ANSWER 1 OF 1 MEDLINE DUPLICATE 1  
96148598 Document Number: 96148598. PubMed ID: 8550069. Regulation and targeting of T-cell immune responses by IgE and IgG **antibodies**. Bheekha Escura R; Wasserbauer E; Hammerschmid F; Pearce A; Kidd P; Mudde G C. (Department of Immuno-Dermatology, SANDOZ Research Institute, Vienna, Austria. ) IMMUNOLOGY, (1995 Nov) 86 (3) 343-50. Journal code: 0374672. ISSN: 0019-2805. Pub. country: ENGLAND: United Kingdom. Language: English.  
AB A set of **chimeric antibodies** with identical F(ab')<sub>2</sub> fragments specific for the hapten 5-iodo-4-hydroxyl-3-nitrophenacetyl (NIP), but with different human Fc parts (gamma 1, gamma 2, gamma 3, gamma 4, epsilon), was used to compare the role of IgG and IgE **antibodies** in antigen presentation by human Epstein-Barr virus (EBV) B cells. Two or three molecules of NIP were coupled to one molecule of Der pI (Der pI-(3)NIP), a major allergen of Dermatophagoides pteronyssinus. Both monomeric IgG and performed complexes of various Der pI/IgG ratios failed to bind significantly to the Fc receptor for IgG on B cells (Fc gamma RII; CD32). Binding of **IgG3** (> IgG1)-containing complexes (optimal ratio of antigen to **antibody** = 1:1) could be enhanced by increasing the number of haptens per Der pI molecule to nine or more. However, antigen presentation mediated by IgG and CD32 was not seen with either pulsed B cells or B cells that were allowed to capture the IgG complexes during the whole stimulation period. IgE binding to **CD23** and subsequent IgE-mediated antigen presentation was seen under all conditions tested. Even monomeric immune complexes (IC) (Der pI-(3)NIP/IgE), in the absence of **CD23** cross-linking, induced an immune response. As the number of natural epitopes for human **antibodies** on Der pI was less than five, we conclude that, in vivo, complexes consisting of Der pI/IgG will be directed to antigen-presenting cells expressing the high-affinity receptor for IgG (CD64), whereas IgE will allow antigen presentation by **CD23**-expressing cells, including B cells.

=> s (reff m?/au or kloetzer w?/au or nakamura t?/au)

L8 43246 (REFF M?/AU OR KLOETZER W?/AU OR NAKAMURA T?/AU)

=> s l8 and anti-IgE antibody  
L9 0 L8 AND ANTI-IGE ANTIBODY

=> s l8 and CD23 antibody  
L10 11 L8 AND CD23 ANTIBODY

=> dup remove l10  
PROCESSING COMPLETED FOR L10  
L11 3 DUP REMOVE L10 (8 DUPLICATES REMOVED)

=> d l11 1-3 cbib abs

L11 ANSWER 1 OF 3 MEDLINE DUPLICATE 1  
2002224456 Document Number: 21957817. PubMed ID: 11962725. Anti-CD23  
monoclonal antibody inhibits germline Cepsilon transcription in B cells.  
Yabuuchi Shingo; **Nakamura Takehiko; Kloetzer William S**  
; **Reff Mitchell E.** (Seikagaku Corporation, Central Research  
Laboratories, Higashiyamato, Tokyo, Japan.. yabuuchi@seikagaku.co.jp) .  
Int Immunopharmacol, (2002 Mar) 2 (4) 453-61. Journal code: 100965259.  
ISSN: 1567-5769. Pub. country: Netherlands. Language: English.

AB A chimeric macaque/human (PRIMATIZED) anti-**CD23 antibody**  
, p6G5G1, demonstrated a strong inhibitory effect on IL-4 and anti-CD40  
antibody-stimulated IgE production by human peripheral blood mononuclear  
cells (PBMCs). RNA analysis by both reverse transcription-polymerase chain  
reaction (RT-PCR) and Northern blot showed that p6G5G1 inhibited germline  
Cepsilon RNA synthesis, but had no effect on CD23 mRNA levels. These data  
suggest that p6G5G1 may inhibit immunoglobulin class switching to IgE  
through the inhibition of germline Cepsilon RNA synthesis. Early addition  
of p6G5G1 after stimulation by IL-4 and anti-CD40 was critical for IgE  
inhibition. In contrast, later addition of p6G5G1 still showed inhibition  
of increased levels of surface CD23, which is normally upregulated by  
stimulation with IL-4 and anti-CD40.

L11 ANSWER 2 OF 3 MEDLINE DUPLICATE 2  
2000150073 Document Number: 20150073. PubMed ID: 10684997. In vitro IgE  
inhibition in B cells by anti-CD23 monoclonal antibodies is functionally  
dependent on the immunoglobulin Fc domain. **Nakamura T;**  
**Kloetzer W S;** Brams P; Hariharan K; Chamat S; Cao X; LaBarre M J;  
Chinn P C; Morena R A; Shestowsky W S; Li Y P; Chen A; **Reff M E.**  
(Seikagaku Corporation, Tokyo Research Institute, Tokyo, Japan. )  
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, (2000 Feb) 22 (2) 131-41.  
Journal code: 7904799. ISSN: 0192-0561. Pub. country: ENGLAND: United  
Kingdom. Language: English.

AB CD23, the low affinity receptor for IgE (FcepsilonRII), is involved in  
regulation of IgE synthesis by B-lymphocytes. Five monoclonal antibodies  
to human CD23 were generated from cynomolgus macaques immunized with  
purified soluble CD23 (sCD23). Four of the five primate antibodies blocked  
the binding of IgE complexes to CD23 positive cells and also inhibited the  
production of IgE in vitro by IL-4 induced human peripheral blood  
mononuclear cells (PBMC). The variable domains of several primate  
antibodies were utilized to construct chimeric macaque/human  
(PRIMATIZED((R))) monoclonal antibodies. PRIMATIZED((R)) p5E8G1,  
containing human gamma 1 constant region, inhibited IgE production in  
vitro as efficiently as the parent primate antibody, but the human gamma 4  
constant version, PRIMATIZED((R)) p5E8G4, was not as effective in IgE  
inhibition. An F(ab')<sub>2</sub> of p5E8G1 did not inhibit IgE production but did  
interfere with IgE inhibition by the intact anti-**CD23**  
**antibody** in a dose dependent fashion. The murine monoclonal  
antibody MHM6 recognizes human CD23 at a different epitope than primate  
antibody 5E8, and inhibits IgE production by IL-4 induced PBMC. As with  
the F(ab')<sub>2</sub> of p5E8G1, the F(ab')<sub>2</sub> of MHM6 also failed to inhibit IgE  
production. These data imply that the mechanism by which anti-**CD23**

**antibodies** inhibit IgE production requires cross-linking of CD23 to an IgG receptor. These data also imply that neither bivalent cross-linking of CD23 alone or inhibition of CD23 binding to its natural ligands is sufficient to inhibit IgE production.

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS

1999:779157 Document No. 132:19632 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same. **Reff, Mitchell R.**; Barnett, Richard Spence; McLachlan, Karen Retta (Idex Pharmaceuticals Corporation, USA). U.S. US 5998144 A 19991207, 43 pp., Cont.-in-part of U.S. 5,830,698. (English). CODEN: USXXAM. APPLICATION: US 1998-23715 19980213. PRIORITY: US 1997-819866 19970314.

AB A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetd. transcriptionally active site previously marked with a marker plasmid (Desmond). This unique site may be bacterial DNA, a viral DNA or synthetic DNA. This Desmond marker plasmid contains the Salmonella HisD gene, the Neomycin phosphotransferase exon 3, the murine dihydrofolate reductase, cytomegalovirus and SV40 enhancers, splice acceptor site, mouse beta globin major promoter, bovine growth hormone polyadenylation site, SV40 early and late polyadenylation sites. The selectable marker proteins may include neomycin phosphotransferase, histidinol dehydrogenase, dihydrofolate reductase, hygromycin phosphotransferase, HSV thymidine kinase, adenosine deaminase, glutamine synthetase, and hypoxanthine-guanine phosphoribosyl transferase. Marked CHO cells were produced and characterized. Other cells that may be marked include myeloma cells, baby hamster kidney cells, COS cells, NSO cells, HeLa cells and NIH 3T3 cells. The method is particularly suitable for the prodn. of mammalian cell lines which secrete mammalian proteins at high levels, in particular Igs. Novel targeting vectors (Molly) and vector combinations for use in the subject cloning method are also provided. This Molly vector contains dihydrofolatereductase, N1+Neomycin phosphotransferase exon1, N2+Neomycin phosphotransferase exon 2, anti-CD20 light chain leader+variable, human kappa const., anti-CD20 heavy chain leader+variable, human gamma 1 const., Salmonella histidinol dehydrogenase, CMV and SV40 enhancers, SV40 origin, splice donor/acceptor, CMV promoter/enhancer, HSV TK promoter and poloma enhancer, mouse beta globin major promoter, SV40 late polyadenylation, bovine growth hormone polyadenylation. Expression of an Anti-CD20 and Anti-human **CD23 antibody** and immunoadhesin in Desmond marked CHO cells was achieved.